Just like the 2020 resolution, Novartis AG’s $25 million 2016 civil resolution Using the SEC involved inappropriate sponsorships of HCPs to conferences and poor payments to HCPs to collect “healthcare data.” The fact that Novartis is currently going through a significantly much larger—and prison—resolution for identical misconduct should